74 research outputs found
Real patient and its virtual twin : application of quantitative systems toxicology modelling in the cardiac safety assessment of citalopram
Abstract. A quantitative systems toxicology (QST) model for citalopram was established
to simulate, in silico, a ‘virtual twin’ of a real patient to predict the occurrence of cardiotoxic
events previously reported in patients under various clinical conditions. The QST model
considers the effects of citalopram and its most notable electrophysiologically active primary
(desmethylcitalopram) and secondary (didesmethylcitalopram) metabolites, on cardiac
electrophysiology. The in vitro cardiac ion channel current inhibition data was coupled with
the biophysically detailed model of human cardiac electrophysiology to investigate the
impact of (i) the inhibition of multiple ion currents (IKr, IKs, ICaL); (ii) the inclusion of
metabolites in the QST model; and (iii) unbound or total plasma as the operating drug
concentration, in predicting clinically observed QT prolongation. The inclusion of multiple
ion channel current inhibition and metabolites in the simulation with unbound plasma
citalopram concentration provided the lowest prediction error. The predictive performance
of the model was verified with three additional therapeutic and supra-therapeutic drug
exposure clinical cases. The results indicate that considering only the hERG ion channel
inhibition of only the parent drug is potentially misleading, and the inclusion of active
metabolite data and the influence of other ion channel currents should be considered to
improve the prediction of potential cardiac toxicity. Mechanistic modelling can help bridge
the gaps existing in the quantitative translation from preclinical cardiac safety assessment to
clinical toxicology. Moreover, this study shows that the QST models, in combination with
appropriate drug and systems parameters, can pave the way towards personalised safety
assessment
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development
Cardiotoxicity is among the top drug safety concerns, and is of specific interest in tuberculosis, where this is a known or
potential adverse event of current and emerging treatment regimens. As there is a need for a tool, beyond the QT interval,
to quantify cardiotoxicity early in drug development, an empirical decision tree based classifier was developed to predict
the risk of Torsades de pointes (TdP). The cardiac risk algorithm was developed using pseudo-electrocardiogram (ECG)
outputs derived from cardiac myocyte electromechanical model simulations of increasing concentrations of 96 reference
compounds which represented a range of clinical TdP risk. The algorithm correctly classified 89% of reference compounds
with moderate sensitivity and high specificity (71 and 96%, respectively) as well as 10 out of 12 external validation
compounds and the anti-TB drugs moxifloxacin and bedaquiline. The cardiac risk algorithm is suitable to help inform early
drug development decisions in TB and will evolve with the addition of emerging data
Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits
Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic parameter. In this study, we measured the pharmacokinetics of a cocktail of three beta blockers after their topical administration into the albino rabbit eye. Samples from aqueous humour were analysed with LC-MS/MS. The pharmacokinetic parameters were estimated using compartmental and non-compartmental analyses. The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%). Absolute ocular bioavailability presented a positive trend with lipophilicity and the values showed approximately 60-fold range. The generated data enhances our understanding for ocular pharmacokinetics of drugs and may be utilized in pharmacokinetic model building in ophthalmic drug development.Peer reviewe
Ocular intracameral pharmacokinetics for a cocktail of timolol, betaxolol and atenolol in rabbits
The mechanisms of drug clearance from the aqueous humor are poorly defined. In this study, a cocktail approach was used to simultaneously determine the pharmacokinetics of three β-blocker agents after intracameral (ic) injection into the rabbit eyes. Aqueous humor samples were collected and analyzed using LC–MS/MS to determine drug concentrations. Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min). Increased compound lipophilicity (atenolol < timolol < betaxolol) resulted in higher clearance and volume of distributions in the aqueous humor. Clearance of timolol and betaxolol is about 10 times higher than the aqueous humor outflow, demonstrating the importance of other elimination routes (e.g., uptake to iris and ciliary body and subsequent elimination via blood flow)
Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail : Tissue exposures in the rabbit eye
Quantitative understanding of pharmacokinetics of topically applied ocular drugs requires more research to further understanding and to eventually allow predictive in silico models to be developed. To this end, a topical cocktail of betaxolol, timolol and atenolol was instilled on albino rabbit eyes. Tear fluid, corneal epithelium, corneal stroma with endothelium, bulbar conjunctiva, anterior sclera, iris-ciliary body, lens and vitreous samples were collected and analysed using LC-MS/MS. Iris-ciliary body was also analysed after intracameral cocktail injection. Non-compartmental analysis was utilized to estimate the pharmacokinetics parameters. The most lipophilic drug, betaxolol, presented the highest exposure in all tissues except for tear fluid after topical administration, followed by timolol and atenolol. For all drugs, iris-ciliary body concentrations were higher than that of the aqueous humor. After topical instillation the most hydrophilic drug, atenolol, had 3.7 times higher AUCiris-ciliary body than AUCaqueous humor, whereas the difference was 1.4 and 1.6 times for timolol and betaxolol, respectively. This suggests that the non-corneal route (conjunctival-scleral) was dominating the absorption of atenolol, while the corneal route was more important for timolol and betaxolol. The presented data increase understanding of ocular pharmacokinetics of a cocktail of drugs and provide data that can be used for quantitative modeling and simulation.Peer reviewe
Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: Introducing time-varying physiology into a paediatric PBPK model
Although both POPPK and physiologically based pharmacokinetic (PBPK) models can account for age and other covariates within a paediatric population, they generally do not account for real-time growth and maturation of the individuals through the time course of drug exposure; this may be significant in prolonged neonatal studies. The major objective of this study was to introduce age progression into a paediatric PBPK model, to allow for continuous updating of anatomical, physiological and biological processes in each individual subject over time. The Simcyp paediatric PBPK model simulator system parameters were reanalysed to assess the impact of re-defining the individual over the study period. A schedule for re-defining parameters within the Simcyp paediatric simulator, for each subject, over a prolonged study period, was devised to allow seamless prediction of pharmacokinetics (PK). The model was applied to predict concentration-time data from multiday studies on sildenafil and phenytoin performed in neonates. Among PBPK system parameters, CYP3A4 abundance was one of the fastest changing covariates and a 1-h re-sampling schedule was needed for babies below age 3.5Â days in order to seamlessly predict PK (<5% change in abundance) with subject maturation. The re-sampling frequency decreased as age increased, reaching biweekly by 6Â months of age. The PK of both sildenafil and phenytoin were predicted better at the end of a prolonged study period using the time varying vs fixed PBPK models. Paediatric PBPK models which account for time-varying system parameters during prolonged studies may provide more mechanistic PK predictions in neonates and infants. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1208/s12248-014-9592-9) contains supplementary material, which is available to authorized users
- …